Skip to main content

Table 2 Statistics for serum Trx1 levels of normal controls and various cancer patients

From: Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses

 

Normal (N) Control

Breast Cancer (BC)

LC* (I-IV)

CRC (I-III)

KC (I/II)

 

NF

NM

NFM

I-III

I

II

III

L

D

# of values

50

50

100

197

66

70

61

106

91

111

63

30

Minimum

14.99

15.61

14.99

26.19

26.19

28.51

28.45

26.19

29.35

13.22

14.77

28.51

25% Percentile

23.98

22.35

23.26

35.53

32.99

35.9

39.45

35.82

34.91

25.23

27.71

25.79

Median

28.5

26.22

27.64

38.98

36

38.97

43.98

39.03

38.98

31.89

31.09

30.96

75% Percentile

32.04

31.97

31.96

44.77

39.08

44.74

50.45

44.72

44.94

37.84

38.29

35.54

Maximum

42.78

42.22

42.78

60.01

48.07

53.37

60.01

56.64

60.01

50

55.02

46.11

Mean

28.62

27.24

27.93

40.12

35.93

40.1

44.67

40.03

40.22

31.71

32.92

31.12

Std. Deviation

6.054

6.155

6.113

6.816

4.346

6.15

6.882

6.793

6.878

8.254

7.864

7.541

Std. Error

0.8561

0.8705

0.6113

0.4856

0.5349

0.7351

0.8812

0.6598

0.721

0.7835

0.9908

1.377

Lower 95% CI

26.9

25.49

26.72

39.16

34.86

38.63

42.91

38.72

38.79

30.16

30.94

28.31

Upper 95% CI

30.34

28.99

29.14

41.08

36.99

41.57

46.43

41.34

41.65

33.26

34.9

33.94

  1. *Abbreviation used: F; Female, M; Male, BC; Breast Cancer, L; lobular carcinoma of breast cancer, D; ductal carcinoma of breast cancer, LC; lung cancer, CRC; colorectal cancer, KC; kidney cancer, CI; confidential interval.